Health Care · Biological Products, (No Diagnostic Substances)

ALLO Allogene Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 173728785 filings
Russell 2000

ALLO at a glance

Allogene Therapeutics, Inc. (ALLO, SEC CIK 1737287) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Allogene Therapeutics, Inc. (ALLO) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $190.9 million. Diluted EPS was -$0.87.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Allogene Therapeutics, Inc. (ALLO) shares worth $255.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Parker Geoffrey M. on October 21, 2026 of 36,342 shares at $1.34 per share.
  • In the last 90 days, ALLO insiders reported 0 open-market purchases ($0) and 1 open-market sale ($49K) on Form 4, a net sale of $49K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
−100.0% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$49K
13F holders
28 funds
$255.3M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added risk: CFO retirement effective November 6, 2026, alongside CEO transition and interim CMO role
  • Most material update: FCA arm discontinued after Grade 5 SAE, with continued patient follow-up potentially triggering regulatory actions
  • Regulatory risk: EU GDPR breaches could incur fines up to €20,000,000 or 4% of annual total revenue
  • Near-term clinical risk: ALPHA3 enrollment delays from anticipated high MRD screen-failure rates
  • Financial risk: $388.9 million in cash and investments as of September 30, 2026, with substantial additional financing required

Management Discussion & Analysis

  • Quarterly revenue $0, versus $0 YoY, with revenue generated exclusively from Overland licensing
  • Net loss $50.4M, versus $41.4M YoY, operating expenses $54.8M versus $44.9M
  • Research and development $41.9M, up $10.8M YoY, driven by cema-cel development and manufacturing reactivation
  • Cash, equivalents and investments $388.9M, runway into Q1 2029, operating cash use $81.0M year to date
  • Capital deployment: $187.9M April offering proceeds and $20.7M ATM proceeds, ALPHA3 enrollment expected complete by end-2027

AI summary of the ALLO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed results and management update for investor review

Item EX-99.1: Item EX-99.1

  • Q3 operating expenses $54.8M, up from $44.9M, reflecting heavier clinical development spending
  • Net loss $50.4M, or $0.15 per share, versus $41.4M, or $0.19 per share, in Q3 2025
Filed Sep 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO Geoffrey Parker retiring from Allogene in all capacities effective November 6, 2026
  • Principal financial officer transition creates near-term succession and execution risk
Filed Aug 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026, announced alongside Allogene’s corporate update
  • Financial details and operating developments contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • ALPHA3 interim data: MRD negativity 58.3% with cema-cel vs 16.7% observation, a 41.6% absolute difference
  • FDA RMAT and Fast Track designations strengthen cema-cel’s regulatory pathway in high-risk 1L LBCL

AI summaries of ALLO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ALLO

Don't miss the next ALLO filing

  • Alerts as it files. A push when ALLO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ALLO, by share count.
  • Ask anything. An AI agent that reads every ALLO filing and answers with sources.

ALLO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Parker Geoffrey M.SellOct 21, 2026$1.34
Douglas Earl MartinSellAug 21, 2026$2.12
Roberts ZacharyAJul 1, 2026-
Roberts ZacharyAJul 1, 2026-
Barrett Elizabeth A.AJun 18, 2026-
Humer Franz BAJun 18, 2026-
Mayo StephenAJun 18, 2026-
Kazam Joshua AAJun 18, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$95K$22K$0
Operating Income-$327.7M-$273.2M-$209.3M
Net Income-$1.6B-$257.6M-$190.9M
Op. Margin-344986.3%-1241813.6%-
Net Margin-1644421.1%-1170863.6%-
Balance Sheet
Total Assets-$548.7M$415.9M
Equity-$422.2M$292.5M
ROE--61.0%-65.3%
Per Share
EPS-$-1.32$-0.87
Cash Flow
Operating CF--$200.3M-$149.2M
CapEx$1.5M$694K$386K

Source: XBRL data in Allogene Therapeutics, Inc. (ALLO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ALLO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ALLO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$255.3M
Q2 202629$339.3M
Q1 202627$239.4M
Q4 202523$120.2M
Q3 202524$114.2M
Q2 202527$97.1M
Q1 202524$110.1M
Q4 202418$163.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 200 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ALLO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 6, 2026Analysis
8-KNov 5, 2026Analysis-
4Oct 23, 2026--
8-KSep 2, 2026Analysis-
4Aug 25, 2026--
10-QAug 12, 2026Analysis
8-KAug 12, 2026Analysis-
SC 13GAug 7, 2026-
4Jul 6, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
8-KJun 22, 2026Analysis-
8-KMay 28, 2026Analysis
10-QMay 13, 2026Analysis
8-KMay 13, 2026Analysis
4Apr 23, 2026--
SC 13GApr 23, 2026-
8-KApr 15, 2026Analysis-
8-KApr 13, 2026Analysis-
8-KApr 13, 2026Analysis-

Related Health Care companies

All Health Care →

ALLO SEC filings: frequently asked questions

Are ALLO insiders buying or selling?

In the last 90 days, Allogene Therapeutics, Inc. (ALLO) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $48,698 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ALLO stock?

As of September 30, 2026, the largest Allogene Therapeutics, Inc. (ALLO) holders among the 13F filers tracked by SignalX were BlackRock ($49.5 million), Citadel Advisors LLC ($39.3 million), Pfizer Inc ($36.4 million), State Street Corp ($26.1 million), Vanguard Capital Management LLC ($19.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ALLO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Allogene Therapeutics, Inc. (ALLO) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $190.9 million. Diluted EPS was -$0.87. The figures come from the XBRL data in the 10-K.

What did ALLO report in its latest 8-K?

Allogene Therapeutics, Inc. (ALLO) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.

What are the latest ALLO SEC filings?

Allogene Therapeutics, Inc. (ALLO) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 23, 2026.

What is ALLO's SEC CIK number?

Allogene Therapeutics, Inc. (ALLO)'s SEC Central Index Key (CIK) is 1737287. EDGAR lists every ALLO filing under that number.

Ask anything about ALLO

The research agent reads ALLO's filings, financials, insider trades and 13F holders, then answers with sources.